Singular Genomics Systems, Inc. (OMIC): Price and Financial Metrics
OMIC Price/Volume Stats
| Current price | $0.88 | 52-week high | $4.80 |
| Prev. close | $0.91 | 52-week low | $0.76 |
| Day low | $0.88 | Volume | 3,596 |
| Day high | $0.93 | Avg. volume | 154,367 |
| 50-day MA | $1.05 | Dividend yield | N/A |
| 200-day MA | $2.01 | Market Cap | 63.69M |
OMIC Stock Price Chart Interactive Chart >
OMIC POWR Grades
- OMIC scores best on the Sentiment dimension, with a Sentiment rank ahead of 56.65% of US stocks.
- The strongest trend for OMIC is in Growth, which has been heading up over the past 179 days.
- OMIC ranks lowest in Momentum; there it ranks in the 5th percentile.
OMIC Stock Summary
- OMIC's price/sales ratio is 46.46; that's higher than the P/S ratio of 96.16% of US stocks.
- With a year-over-year growth in debt of 255.94%, SINGULAR GENOMICS SYSTEMS INC's debt growth rate surpasses 94.41% of about US stocks.
- As for revenue growth, note that OMIC's revenue has grown 112.81% over the past 12 months; that beats the revenue growth of 94.43% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to SINGULAR GENOMICS SYSTEMS INC are PSNL, WATT, MNTS, MIRM, and CYN.
- Visit OMIC's SEC page to see the company's official filings. To visit the company's web site, go to singulargenomics.com.
OMIC Valuation Summary
- OMIC's price/earnings ratio is -0.9; this is 103.73% lower than that of the median Healthcare stock.
- Over the past 24 months, OMIC's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for OMIC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| OMIC | 2023-05-23 | 49.6 | 0.3 | -0.9 | -0.1 |
| OMIC | 2023-05-22 | 46.0 | 0.3 | -0.8 | 0.0 |
| OMIC | 2023-05-19 | 39.8 | 0.3 | -0.7 | 0.1 |
| OMIC | 2023-05-18 | 35.4 | 0.2 | -0.6 | 0.2 |
| OMIC | 2023-05-17 | 35.3 | 0.2 | -0.6 | 0.2 |
| OMIC | 2023-05-16 | 36.3 | 0.2 | -0.6 | 0.1 |
OMIC Price Target
For more insight on analysts targets of OMIC, see our OMIC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $30.33 | Average Broker Recommendation | 1.6 (Moderate Buy) |
Singular Genomics Systems, Inc. (OMIC) Company Bio
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. It manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits; and offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution. The company was incorporated in 2016 and is headquartered in La Jolla, California.
Latest OMIC News From Around the Web
Below are the latest news stories about SINGULAR GENOMICS SYSTEMS INC that investors may wish to consider to help them evaluate OMIC as an investment opportunity.
Singular Genomics to Present at the Goldman Sachs Global Healthcare ConferenceSAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA. Singular Genomics’ management is scheduled to participate in a fireside chat Tuesday, June 13, 2023, at 11:20 a.m. Pacific Time / 2:20 p.m. Eastern Time. Investors an |
Singular Genomics Systems (NASDAQ:OMIC) shareholders are up 20% this past week, but still in the red over the last yearThis week we saw the Singular Genomics Systems, Inc. ( NASDAQ:OMIC ) share price climb by 20%. But that doesn't change... |
Q1 2023 Singular Genomics Systems Inc Earnings CallQ1 2023 Singular Genomics Systems Inc Earnings Call |
Singular Genomics Reports Recent Highlights and First Quarter 2023 Financial ResultsSAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the first quarter ended March 31, 2023. “We had a productive first quarter, highlighted by shipping three additional G4 systems to a diverse set of customers,” said Drew Spaventa, Chairman and Chief |
Singular Genomics to Report First Quarter 2023 Financial Results on May 9, 2023SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the first quarter 2023 after the market close on Tuesday, May 9, 2023. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors int |
OMIC Price Returns
| 1-mo | -16.98% |
| 3-mo | -53.68% |
| 6-mo | -51.65% |
| 1-year | -73.65% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -56.22% |
| 2022 | -82.61% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...